Glyph Allopregnanolone

Seaport Therapeutics由曾开发出精神分裂症重磅药物KarXT的团队创立，2026年5月登陆纳斯达克首日大涨超20%。公司利用Glyph淋巴靶向前药平台，对已验证机制的CNS药物进行“老药新做”，解决了口服生物利用度与肝毒性难题。其策略启示中国企业：与其追逐高风险的first-in-class靶点，不如聚焦已验证机制的优化改良，以更低风险实现差异化突破。 引言：一场140亿美元并购后的“二次创业” 2023年12月，百时施贵宝（BMS）以140亿美元收购Karuna Therapeutics的消息震惊了整个医药界。这笔交易让背后的孵化者PureTech Health赚得盆满钵满——最初仅投入1850万美元，最终带来了约11亿美元的现金收益，外加未来最高4亿美元的里程碑付款和销售分成。 而就在这笔交易达成仅4个月后，PureTech Health的创始人兼前CEO Daphne Zohar带着原班人马，成立了一家新公司——Seaport Therapeutics。2026年5月1日，Seaport在纳斯达克上市首日股价大涨超20%，市值突破11亿美元。 这家公司凭什么在成立两年内就成功IPO？它的“老药新做”策略能给中国创新药企带来什么启示？ 本文将结合公开信息，包括Endpoint News对CEO Daphne Zohar和CSO Michael Chen的独家访谈，为您深度拆解。 一、从“单产品”到“平台+管线”：CNS研发模式的进化 1.1 Karuna的“遗憾”：单一产品的融资困境 Zohar在访谈中坦诚地回顾了Karuna的创业经历：“当我们创立Karuna时，最大的问题是融资困难，因为它本质上是一个‘单一产品’的公司”。这种单打独斗的模式风险极高——一旦核心管线失败，公司将面临灭顶之灾。 这也是为什么PureTech Health采用“Hub-and-Spoke”（中心辐射）模式的原因。这一模式并非Seaport独创，但在生物医药领域，PureTech Health、Roivant、BridgeBio等都是典型案例。其核心逻辑是：母公司（Hub）负责融资、管理、商业化等支持性工作，而子公司（Spoke）则专注于研发，保持创业团队的灵活性和激励机制。 1.2 Seaport的升级：Glyph平台赋予的“多重保险” 与Karuna不同，Seaport从一开始就拥有三大优势：“我们拥有新颖的IP、Glyph平台以及丰富的管线”。 正是这种平台化思维，使Seaport能够在半年内完成两轮融资，总额高达3.25亿美元——A轮1亿美元由ARCH Venture Partners、Sofinnova Investments、Third Rock Ventures等顶级机构领投，B轮2.25亿美元则由General Atlantic领投，T. Rowe Price、Foresite Capital等跟投。 对中国药企的启示：在资本寒冬中，单靠一个靶点或一个分子的故事越来越难打动投资者。拥有平台技术或多管线布局的企业，能够分散风险、创造更多价值节点，从而获得更高的资本认可。 二、Glyph平台：破解CNS药物“口服难”的技术密码 2.1 技术原理：让药物“伪装”成膳食脂肪 Seaport的核心技术Glyph平台，源自澳大利亚莫纳什大学Christopher Porter教授团队的开创性工作。其设计灵感来源于人体对膳食脂肪的自然处理方式——将药物与膳食脂肪分子可逆结合，形成新型前药，使药物口服后随脂肪分子绕过肝脏，直接进入肠道淋巴系统。 这一机制解决了两个关键问题： —绕过肝脏首过代谢：传统口服药物进入肝脏后，大量有效成分被代谢掉，导致生物利用度低。而Glyph将药物通过淋巴系统运输，避免了肝脏的“首过效应”。 —降低肝毒性：对于阿戈美拉汀等具有肝毒性的药物，Glyph能显著减少肝脏暴露，甚至消除肝功能监测的需求。 2.2 “多面手”的灵活性：解决不同分子的不同问题 Chen博士在访谈中特别强调：“平台是不是只会一招？答案是，它实际上可以解决不同的问题。” 以Seaport的两款核心管线为例： SPT-300（口服别孕烷醇酮前药）：别孕烷醇酮是一种内源性神经类固醇，具有经临床验证的快速抗抑郁和抗焦虑活性。但此前Sage Therapeutics开发的布瑞诺龙（Zulresso）需要在医疗中心连续静脉输注60小时，极大限制了可及性。Sage后续推出的口服衍生物珠兰诺隆（Zurzuvae）虽解决了口服问题，但仍面临肝毒性和首过代谢的挑战。SPT-300通过Glyph技术，在保持内源性别孕烷醇酮全部药理活性的同时，实现了约9倍于第三方报告数据的口服生物利用度。 SPT-320（口服阿戈美拉汀前药）：阿戈美拉汀在欧洲和澳大利亚已被批准为抗抑郁药，但由于高首过代谢导致肝损伤风险，始终未能进入美国市场。SPT-320利用Glyph绕开肝脏，有望以更低剂量实现同等疗效，同时免去肝功能监测的麻烦。 对中国药企的启示：与其追求全新的“first-in-class”靶点，不如聚焦那些在临床上已证实有效、但因给药方式或毒性问题而被限制的药物。这种“老药新做”的策略，研发风险更低、临床转化更快，尤其适合资源有限的biotech公司。 三、管理团队：CNS领域的“梦之队” 3.1 核心人物：从Karuna到Seaport的传承 Seaport的管理团队可谓群星璀璨： —Daphne Zohar（CEO）：PureTech Health创始人兼前CEO，16岁开始创业的连续创业者。PureTech Health及其实体公司进行的临床试验成功率高达80%，是行业平均水平的约6倍。 —Steven Paul（董事会主席）：前礼来研发总裁，曾负责奥氮平、度洛西汀、xanomeline等CNS药物的开发；后担任Karuna CEO，也是Sage Therapeutics的联合创始人。 —Michael Chen（CSO）：负责Glyph平台的转化研究工作。 —Antony Loebel（CMO）：2024年6月加入，曾任Sunovion高管，是美国神经精神药理学学院院士，拥有超过20年的CNS药物开发经验。 这样的团队配置，确保了Seaport在策略制定、技术转化、临床执行等关键环节都有顶尖专家把关。 3.2 从Karuna学到的“临床设计”教训 在访谈中，Chen博士多次提到“从Karuna学到的经验”。最核心的一点是：精神病学临床试验的高安慰剂效应是可控的。 “安慰剂率是Karuna处理得非常出色的一个问题，我们在Seaport也高度关注——临床试验设计中那些已被证明会量化加剧安慰剂反应的特定要素。” 这包括患者筛选标准、期望管理、评估工具选择等多个细节。Chen博士坦言：“没有一颗神奇的银弹能解决所有安慰剂问题，现实是需要做好无数的小事。” 对中国药企的启示：国内精神类药物研发往往低估了临床试验设计的复杂性，特别是在患者招募、评分员培训等方面。成功经验告诉我们，精细化的临床运营能力与药物本身同样重要。 四、CNS领域的“复兴”与Seaport的定位 4.1 大药企“回归”与Biotech的“灵活” 过去十年，大多数大型制药公司因CNS研发失败率高而纷纷退出这一领域。但随着KarXT的获批、BMS 140亿美元收购Karuna、强生146亿美元收购Intra-Cellular Therapies等一系列标志性事件，CNS领域正在经历一场“复兴”。 Zohar观察到：“大型药企肯定有重燃的兴趣……但它们的退出已成事实，现在回归的原因是这些适应症的影响实在太大了。通常Biotech在这方面更灵活，能够将想法推进到某个节点。” 4.2 聚焦已验证机制：降低转化风险 Seaport选择了一条与众不同的道路——不做全新的、未经验证的机制，而是聚焦那些已有临床证据、但因某些“硬伤”而受限的分子。 正如Zohar所说：“神经精神病学最大的挑战之一是，未经验证的机制从临床前到临床概念验证的转化率很低。我们的策略不是猜测一个新机制在动物身上有效就以为能在人身上有效。” 这种策略呼应了Chen博士的观点：“从Karuna到Seaport，一切都归结为临床证据的重量。” 对中国药企的启示：国内不少CNS企业在追逐“first-in-class”靶点，但高失败率往往令人望而却步。Seaport的策略提供了一条“中间路线”——用已验证机制+创新递送平台，实现差异化竞争。 五、未来展望与风险提示 5.1 关键催化剂节点 Seaport的核心管线SPT-300目前处于IIb期临床（BUOY-1试验），预计2027年上半年公布数据。SPT-320已完成I期阳性结果，即将进入II期。SPT-348（非致幻性神经塑形剂）仍处于临床前阶段，但受益于华盛顿对精神药物研究的政策支持，前景可期。 5.2 不容忽视的风险 —临床失败风险：CNS领域历史成功率极低，II期到III期的转化尤其困难。 —竞争压力：Alto Neuroscience、Cybin、MindMed等多家biotech也在推进CNS领域的创新疗法。 —商业化挑战：即使SPT-300成功上市，如何与Sage、Sarepta等公司的产品竞争，仍是未知数。 —资金需求：公司2025年净亏损7490万美元，至今尚无产品销售收入，未来仍需持续融资。 结语：中国药企能学什么？ Seaport Therapeutics给中国创新药企带来了几点重要启示： 1. “老药新做”≠缺乏创新：通过先进的递送技术解决已知药物的痛点，是降低研发风险、加速临床转化的有效路径。 2. 平台+管线的商业模式更具韧性：在资本寒冬中，多管线布局能分散风险，创造更多价值节点。 3. 经验丰富的团队是最大的“护城河”：Seaport的超高融资效率与IPO成功，核心在于其团队在CNS领域积淀的深厚经验与成功案例。 4. 临床试验设计需要精细化运营：精神病学试验中的安慰剂效应管理、患者筛选等细节，往往决定了试验成败。 当然，Seaport的故事还远未结束。SPT-300的IIb期数据能否延续早期的惊艳表现？Glyph平台能否持续孵化出差异化的重磅药物？这些问题将在未来两年内给出答案。但无论如何，Seaport已经为CNS领域的“老药新做”模式，提供了一个值得借鉴的标杆。 Copyright©2026. All Rights Reserved. 免责申明：本文章内容基于公开信息整理，由AI辅助生成，旨在分享知识，仅供参考，不构成任何专业建议或承诺，不代表本公众号立场。用户须自行甄别所获信息的真实程度及适用条件，并完全承担因使用该信息所引发的一切后果与责任。

Seaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. Shares rose $SPTX more than 20%. With a team largely made up of Karuna Therapeutics veterans, Seaport is looking to push even further in neuroscience and central nervous system disorders. Karuna developed the schizophrenia drug KarXT and was acquired for $14 billion by Bristol Myers Squibb. KarXT was approved as Cobenfy in late 2024. Endpoints News sat down virtually with Seaport CEO Daphne Zohar and CSO Michael Chen to discuss the company’s path to an IPO, its “Glyph” platform and what comes next. The following transcript has been substantially edited for length and clarity. Max Gelman: Thanks for chatting with me today. Let’s start broadly here: What was there to build on from Karuna? Daphne Zohar: We actually have some advantages that we didn’t have when we were founding Karuna. We have novel IP, we have the Glyph platform, and we also have a robust pipeline. When we were founding Karuna, that was an issue that held us back from raising financing. Karuna was kind of like a one-product thing. If you look at this area of neuropsychiatry, one of the biggest challenges has been that unvalidated mechanisms have had a poor translation from preclinical to clinical proof-of-concept. We’re taking a different approach than just saying we’re going to start with this entirely new mechanism that works in animals and try to guess how it’s going to work in humans. Gelman: Was the development of the Glyph platform intertwined with the invention of KarXT? Or did they come about on parallel paths? Zohar: There’s not an overlap in terms of the technical approach to solving the issue. In the case of the Glyph platform, that’s entirely separate from the KarXT invention. The way that this technology came about was that scientists at Monash University [in Australia] were working on how to traffic drugs through the lymphatic system. By applying Glyph, you’re cloaking a drug so the body thinks it’s a dietary fat, and then it takes up through the lymphatic system instead of through the typical path, which hits the liver first. Michael Chen: Around that philosophical overlap, a lot of it from Karuna to Seaport comes down to the weight of clinical evidence. At Karuna, there was clinical evidence of xanomeline, and then we solved a key problem. That pattern recognition also applies at Seaport, where everything that we’re working on has had clinical evidence from the parent molecule, but is weighed down by some drawback. Gelman: So the main advantage of the platform is making drugs that are more easily absorbed? Chen: I think part of what you may be getting at is, is the platform a one-trick pony? And the answer is, it can solve, actually, a different number of problems. In the case of our first program, SPT-300, it couldn’t be taken as a pill until we “Glyphed” — if you want to use it as a verb — that molecule. In the case of our second program, SPT-320, that is a drug that can actually lead to liver enzyme elevations. But by “Glyphing” the molecule, we were able to substantially increase the oral bioavailability. Even though the platform is the same, it’s actually solving different problems for the different drugs in our pipeline. Gelman: What is there to explore beyond the first two molecules, if you want to “Glyph” the drugs together, or however you want to phrase it? I don’t know if I’m using that correctly. Chen: Yeah, we use it as a verb all the time internally. So we’re also developing a “non-hallucinogenic neuroplastogen.” We like to call it a psychedelic without the trip, because it has the same pharmacology. We are “Glyphing” that to turn it into a potential new medicine. While Seaport is focused on CNS, the platform is not just specific to getting into the brain. Gelman: It’s interesting you bring that up because there’s been a renewed push in Washington to fast-track psychedelic drug access . How is Seaport planning to leverage this more favorable environment? Zohar: It’s great. These are really interesting regulatory tailwinds for mental health, mental illness. Our program is something you could take at home and potentially have this similar benefit as medicines taken under supervision. Obviously, this has to be proven out in the clinic, but that would have a much further-reaching impact. Chen: We’ll see how it evolves. Just the attention to mental health in general has been huge, and we’re starting to see more specific initiatives. We’re certainly keeping our ears to the ground around this. Gelman: What are some of the specific things you’re spending the IPO money on, and how do you plan to spend it responsibly? Zohar: For example, CMC — so creating the drug product that is going to be dosed in patients. The planning and implementing the clinical studies. Those are the types of things. In the case of some of our discovery and preclinical work, we are able to advance a number of those programs. Gelman: What do you consider to be the most challenging parts of CNS research that the field continues to face? Zohar: One way that we’re tackling it is this idea of unvalidated mechanisms, which we’ve discussed already. Another area relates to clinical design and execution. Chen: That’s where we go back to a strategy of identifying the mechanisms that have shown to be active. So many times, you struggle to take a mechanism that seems like it works in the dish or in a mouse, and show that it works in a human, and then you layer on the difficulty of running a clinical trial, and it can be very challenging. Karuna really opened this up. Gelman: Okay, so on the clinical trial side, psychiatry studies tend to have high placebo rates for a number of reasons. How do you ameliorate this problem with the platform? Chen: The placebo rate was something that Karuna managed really well, and it’s something we’re paying a lot of attention to at Seaport — specific elements of clinical trial design that have been shown now to quantifiably exacerbate that placebo response. I wish we could say there’s one silver bullet that magically solves all placebo responses, but the reality is it’s a lot of little things that have to be done. Gelman: How do you see the state of CNS research in the industry, and where does it go from here? Zohar: There’s a number of really interesting things happening in CNS more broadly, like the Denali approval recently . Voyager’s got some really interesting technologies in that area too. We’re also intrigued by various biomarkers, including EEG-based biomarkers to help identify responders and non-responders. That’s still pretty early days though. Chen: We do feel like this is a transition point where psychiatry in particular is going to get more and more precise as we go, whether that’s based on biomarkers or even just simple classifications. The field is going to hopefully start moving away from thinking about these broad disorders as homogeneous and start thinking a little bit more precisely about matching a mechanism to a particular patient. Gelman: Are CNS research and psychiatry more of a biotech thing now, rather than a Big Pharma thing, after several companies exited the space in the late 2010s? Zohar: There’s definitely a renewed interest on the part of pharma companies. Then there’s obviously some very big acquisitions that have happened over the last few years. But they did move away, and I think that they’re moving back partly because these indications are so impactful. In general, biotech tends to be a little bit more nimble at taking these ideas forward to a certain point. Gelman: Thanks so much for your time today. Editor’s note: This article has been updated to include information on Seaport’s stock movement.